Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J.P. Morgan: News And Observations From Our Reporters’ Notebooks

Executive Summary

At breakout sessions for Genzyme Corp. and Sanofi-Aventis SA, their respective CEOs were unsurprisingly mum on their merger and acquisition tussle, though some were amused to hear Sanofi's Christopher Viehbacher say, “Most M&A has not created shareholder value, companies are too quick to pay more than they should." That statement of course will leave him, if the deal is consummated, to explain how buying Genzyme isn't like "most" M&A.
Advertisement

Related Content

Lilly/BI Eye Diabetes Leadership In Expansive Risk-Sharing Collaboration
Lilly/BI Eye Diabetes Leadership In Expansive Risk-Sharing Collaboration

Topics

Advertisement
UsernamePublicRestriction

Register

PS053040

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel